Group 1 - The stock of Giant Bio (02367) has fallen over 4%, reaching a new low of 47.92 HKD since January this year, with a trading volume of 4.57 billion HKD [1] - According to Zheshang Securities, the cosmetics industry is experiencing a weak Q3, with some key brands showing a decline in growth on Douyin [1] - Giant Bio's GMV on Douyin increased by 15% year-on-year in Q3, with specific brands like Kefu Mei growing by 5% and Keli Jin by 78% [1] Group 2 - The company is focusing on the upcoming Double Eleven sales event in the second half of the year [1] - There are ongoing issues regarding the recombinant collagen products of Kefu Mei, with Huaxi Bio reporting that several third-party testing results indicate that the collagen content does not meet standards [1] - Huaxi Bio has submitted dozens of test reports to the National Medical Products Administration [1]
港股异动 | 巨子生物(02367)逆势跌超4%创9个月新低 市场关注双十一可复美销情